Article Text


P17.35 Cost-effectiveness analysis of abacavir-based and tenofovir-based regimens in singapore
  1. YY Ong,
  2. G Hoo,
  3. HL Law,
  4. OT Ng
  1. Tan Tock Seng Hospital, Singapore


Introduction Human immunodeficiency virus (HIV) infection has evolved into a chronic disease with the use of highly active antiretroviral therapy (HAART). As survival rates improve and the duration of treatment increases, cost of treatment will be a major factor affecting the choice of HAART.

Objective To assess the cost-effectiveness of abacavir-based and tenofovir-based regimens in Singapore.

Methods This was a single-centre, retrospective study. Data was obtained from online medical records and hardcopy case files. HIV-positive patients on each regimen were matched according to age group, gender, race, body mass index and HAART. An incremental cost-effectiveness ratio (ICER) analysis was performed to evaluate the cost-effectiveness between abacavir (ABC)-based and tenofovir (TDF)-based regimens between the evaluation period of week 12 to 36 and week 37 to week 60. Costs were reported in Singapore dollars (S$).

Results Two hundred and thirty patients were analysed (82.2% Chinese, 91.3% male, age: 46.0 ± 13.0 years old), 115 patients in each group. The most common used combinations were ABC, lamivudine (3TC) and efavirenz (EFV) (76.5%), and TDF, 3TC and EFV (78.2%); followed by ABC, 3TC, boosted atazanavir (ATV/r) (13.0%), and TDF, 3TC and ATV/r (11.3%). Majority of the patients in each arm were at least 95% adherent to their medication regimens (93.0% and 91.3% for ABC and TDF group respectively). For both evaluation periods, more patients in ABC group obtained undetectable viral load (77.4% vs 59.1% and 81.7% vs 76.5%). The ICER value was –S$13348.72 for the period of week 12 to 36 and –S$19085.37 for the period of week 37 to week 60.

Conclusion ABC-based regimen was found to be more cost-effective than TDF-based regimen with similar virologic control rates in HIV patients in Singapore. This can translate to public healthcare cost savings in the near future.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.